Susceptibility of Glycopeptide-Resistant Enterococci to Linezolid, Quinupristin/dalfopristin, Tigecycline and Daptomycin in a Tertiary Greek Hospital

We investigated the antibiotic susceptibility of glycopeptide-resistant enterococci (GRE). Seventy consecutive GRE were tested. Sixty-two isolates were identified as Enterococcus faecium (88.6%), and 8 (11.4%) as Enterococcus faecalis. All strains were susceptible to linezolid and daptomycin, while 17.1% (12/70) and 11.4% (8/70) were resistant to quinupristin/dalfopristin (QD) and tigecycline, respectively. All E. faecalis isolates were resistant to QD, while 4 of 62 (6.5%) E. faecium isolates were resistant to QD. All E. faecalis isolates were susceptible to tigecycline, while 14.5% (9/62) E. faecium isolates were resistant. Continued surveillance of GRE antibiotic susceptibilities is important for combating these multi-resistant nosocomial pathogens.

[1]  S. Stefani,et al.  Longitudinal Assessment of Antimicrobial Susceptibility among Gram-Negative and Gram-Positive Organisms Collected from Italy as Part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011 , 2013, Pharmaceuticals.

[2]  Yan Sun,et al.  The emergence of clinical resistance to tigecycline. , 2013, International journal of antimicrobial agents.

[3]  H. Fang,et al.  Evaluation of species-specific PCR, Bruker MS, VITEK MS and the VITEK 2 system for the identification of clinical Enterococcus isolates , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  Chun-Eng Liu,et al.  Trends in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Tigecycline, Daptomycin, and Linezolid and Molecular Epidemiology of the Isolates: Results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) Study, 2006 to 2010 , 2012, Antimicrobial Agents and Chemotherapy.

[5]  B. Coignard,et al.  Changing trends in vancomycin-resistant enterococci in French hospitals, 2001-08. , 2011, The Journal of antimicrobial chemotherapy.

[6]  Paulo Roberto da Silva,et al.  Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study. , 2011, Revista da Sociedade Brasileira de Medicina Tropical.

[7]  A. Tsakris,et al.  Trends in antimicrobial resistance of clinical isolates of Enterococcus faecalis and Enterococcus faecium in Greece between 2002 and 2007. , 2010, The Journal of hospital infection.

[8]  A. Maniatis,et al.  A newly described vancomycin-resistant ST412 Enterococcus faecium predominant in Greek hospitals , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  B. Murray,et al.  Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, New England Journal of Medicine.

[10]  M. Zilberberg,et al.  Secular Trends of Hospitalization With Vancomycin-Resistant Enterococcus Infection in the United States, 2000–2006 , 2009, Infection Control & Hospital Epidemiology.

[11]  Do Kyung Lee,et al.  Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005). , 2007, Journal of biochemistry and molecular biology.

[12]  Ronald N. Jones,et al.  Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. , 2007, Diagnostic microbiology and infectious disease.

[13]  Ronald N. Jones,et al.  Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005) , 2007, BMC infectious diseases.

[14]  K. Waites,et al.  Nosocomial Spread of Enterococcus faecium Resistant to Vancomycin and Linezolid in a Tertiary Care Medical Center , 2006, Journal of Clinical Microbiology.

[15]  J. Jernigan,et al.  Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. , 2005, The Journal of infectious diseases.

[16]  D. Livermore,et al.  Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid. , 2004, International journal of antimicrobial agents.

[17]  F. Chang,et al.  Vancomycin-resistant enterococcus (VRE) carriage and infection in intensive care units. , 2004, Microbial drug resistance.

[18]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[19]  D. Livermore,et al.  Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. , 2000, The Journal of antimicrobial chemotherapy.

[20]  W. Bilker,et al.  Enterococcal Bacteremia: Risk Factors for Vancomycin Resistance and Predictors of Mortality , 1999, Infection Control & Hospital Epidemiology.